BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16369811)

  • 1. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
    Kiran H; Kiran G
    Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
    Pan HA; Wang ST; Pai MC; Chen CH; Wu MH; Huang KE
    J Reprod Med; 2003 May; 48(5):375-80. PubMed ID: 12815913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
    Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
    Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.
    Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC
    Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate.
    Uygur D; Yeşildaglar N; Erkaya S
    Gynecol Endocrinol; 2005 Apr; 20(4):209-12. PubMed ID: 16019363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study.
    Koh KK; Ahn JY; Jin DK; Yoon BK; Kim HS; Kim DS; Kang WC; Han SH; Choi IS; Shin EK
    Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1889-94. PubMed ID: 12933531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions.
    Guvenal T; Durna A; Erden O; Guvenal F; Cetin M; Cetin A
    Adv Ther; 2009 Aug; 26(8):805-11. PubMed ID: 19672567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of DNA damage in postmenopausal women under hormone replacement therapy.
    Ozcagli E; Sardas S; Biri A
    Maturitas; 2005 Jul; 51(3):280-5. PubMed ID: 15978971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S; Moghasemi M; Faghihzadeh S
    Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Creatsa MG; Economou EV; Siasou Z; Panoulis CP; Kalligerou I; Papadias C
    Climacteric; 2008 Apr; 11(2):155-65. PubMed ID: 18365858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.
    Skouby SO; Sidelmann JJ; Nilas L; Jespersen J
    Hum Reprod; 2007 Apr; 22(4):1186-91. PubMed ID: 17204528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
    Bots ML; Evans GW; Riley W; McBride KH; Paskett ED; Helmond FA; Grobbee DE;
    Eur Heart J; 2006 Mar; 27(6):746-55. PubMed ID: 16415304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women.
    Sezer Ozer K; Erenus M; Yoldemir T
    Climacteric; 2009 Feb; 12(1):66-71. PubMed ID: 19012050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.